Smarter News Now
  • About Us
  • Privacy Policy
  • Terms & Conditions
  • Contact Us
  • Email Whitelisting
No Result
View All Result
  • Top News
  • Economy News
  • Forex News
  • Investing News
  • Stock News
  • Politics News
  • Editor’s Pick
  • Top News
  • Economy News
  • Forex News
  • Investing News
  • Stock News
  • Politics News
  • Editor’s Pick
No Result
View All Result
Smarter News Now
No Result
View All Result
Home Stock News

Sanofi eyes approval of COVID-19 vaccine by first half of 2021

by
June 23, 2020
in Stock News, Top News
0
Sanofi eyes approval of COVID-19 vaccine by first half of 2021
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter
imageCoronavirus9 hours ago (Jun 23, 2020 12:17PM ET)

(C) Reuters. Sanofi logo is seen in Paris

By Matthias Blamont

PARIS (Reuters) – French drugmaker Sanofi (PA:SASY) SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain’s GlaxoSmithKline (NYSE:GSK) Plc by the first half of next year, faster than previously anticipated.

Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021.

“We are being guided by our dialogue with regulatory authorities,” Sanofi research chief John Reed told reporters, when asked about the accelerated time frame.

There are currently no vaccines to prevent the coronavirus that has infected more than 9 million people and killed over 469,000 globally, and only a couple of medicines that have demonstrated benefit in hospitalized COVID-19 patients in clinical trials.

Many drugmakers are racing to come up with a safe and effective vaccine that can be produced at large scale.

Moderna (NASDAQ:MRNA) Inc, the University of Oxford in collaboration with AstraZeneca (NYSE:AZN) Plc, and an alliance of BioNTech and Pfizer Inc (NYSE:PFE) grabbed headlines by moving to human trials as early as March.

Sanofi Chief Executive Paul Hudson (NYSE:HUD) said the firsts in the race now were not assured of securing victory.

“There are companies moving faster, but let us be brutally clear, speed has three downsides,” he said of competition.

“They are using existing work, in many cases done for SARS; it is likely not to be as efficacious; and there is no guarantee on supply in large volumes,” Hudson said.

The probability of success for Sanofi is “higher than anybody else,” the CEO said.

The comments echoed those of GSK, whose chief medical officer for vaccines told Reuters on Friday the company was aiming at quality before speed.

Sanofi, whose Pasteur vaccines division has a long established reputation, notably in flu, is currently working on two vaccine projects.

One uses an adjuvant made by GSK to potentially boost its efficacy. It has received financial support from the U.S. Biomedical Advanced Research and Development Authority (BARDA).

The other, being developed with U.S. company Translate Bio (NASDAQ:TBIO) Inc, relies on a different technology known as mRNA, similar to the Moderna approach.

Clinical trials of the vaccine developed with GSK, described as a recombinant vaccine because of the use of GSK’s boosting adjuvant, are to start in September. Trials of the mRNA vaccine candidate should begin around the end of the year, the company said.

Sanofi said it had capacity to produce up to 1 billion doses a year of its recombinant vaccine, and that it would be able to supply up to 360 million doses of its mRNA vaccine annually.

In April, Sanofi said it had manufacturing capacity for 600 million doses for its recombinant vaccine, with the ambition to double production by mid-2021.

The company also said it would expand its collaboration with Translate Bio on developing vaccines, in a deal which will give the U.S. group $425 million in upfront payments.

Sanofi eyes approval of COVID-19 vaccine by first half of 2021

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

ShareTweetPin

Related Posts

Editor's Pick

The New Canadian Business Is Here!

October 4, 2021
The New Canadian Business Is Here!
Editor's Pick

The New Canadian Business Is Here!

October 4, 2021
bose corp
Top News

Bose Stock: Advantages of Investing in the Modern Audio Business

July 13, 2021
HEB store
Top News

What Is the HEB Grocery Stock Price & Value?

July 7, 2021
OnlyFans logo
Top News

OnlyFans Stock: What Is the Point to Invest in Popular Adults Only Service?

July 6, 2021
what is IV crush
Top News

IV Crush: Why You Should Be Aware of a Volatility Crush

June 23, 2021
Next Post
Stiglitz Urges Capitalism Rethink as Roubini Invokes Stagflation

Stiglitz Urges Capitalism Rethink as Roubini Invokes Stagflation

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Email Address *
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
 

Recommended

Tweet that Trump will accept nomination in Charlotte is incorrect -Fox News reporter

Tweet that Trump will accept nomination in Charlotte is incorrect -Fox News reporter

July 30, 2020

Germany beats Ukraine 2-1 for first win in four games

October 11, 2020

Why buying life insurance is an act of love

November 6, 2021
Fed’s Harker says he expects ‘sharp recession’ in 2020 with growth next year

Fed’s Harker says he expects ‘sharp recession’ in 2020 with growth next year

June 16, 2020

The Chancellor is prolonging the agony by extending the furlough yet again

March 3, 2021
Delta Air expects quarterly revenue to fall by $10 billion, beefs up line of credit

Delta Air expects quarterly revenue to fall by $10 billion, beefs up line of credit

March 20, 2020
  • About Us
  • Privacy Policy
  • Terms & Conditions
  • Contact Us
  • Email Whitelisting

Copyright © 2022 SmarterNewsNow.
All Rights Reserved.

Disclaimer: SmarterNewsNow.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.
The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

No Result
View All Result
  • About Us
  • Contact Us
  • Email Whitelisting
  • Home
  • Privacy Policy
  • Terms & Conditions
  • Thank You

Copyright © 2020 SmarterNewsNow. All Rights Reserved.